Xiaowei Ding

Cofounder, VoxelCloud

Search every verified Xiaowei Ding interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Xiaowei Ding, CEO of Voxelcloud, spoke at SVFF2017 about the company's work in imaging-centered medical analytics, combining cloud computing and artificial intelligence to support clinical diagnosis. He described Voxelcloud's products, including a low-dose chest CT solution for pulmonary disease and lung cancer screening, as well as applications for ultrasound, X-ray, and eye diseases such as diabetic retinopathy and age-related macular degeneration. Ding noted that the company had collected over 16 million cases of data from about 100 hospitals in the U.S. and China and had submitted five product applications to the China FDA, with preparations underway for U.S. FDA clearance. Ding also outlined Voxelcloud's goal to provide accessible diagnosis by expanding the capacity of large hospitals while delivering similar quality medical services to rural areas. He mentioned plans to release what he described as the world's first liquid biopsy plus imaging solution for cancer screening, developed in collaboration with a UCLA spinoff called Early Diagnosis, which uses ctDNA technology for early lung and liver cancer screening. He stated that the company's approach involves merging imaging features with ctDNA data, and that Voxelcloud had offices in Los Angeles, Beijing, Shanghai, and Phoenix, with staff from institutions including UCLA, Mayo Clinic, and CMU.